| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief R&D Officer | SVP Clinical Development, CMO | VP Clinical Development, CMO
2 companies
Thackray Helen M. serves as a Chief R&D Officer at BCRX and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 1 buy and 13 sells. Those positions are worth an estimated $2.8M at current prices.
Historically, Thackray Helen M.'s trades have earned a strong insider score of 78/100 across 4 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +55.1%.
The biggest single holding is BCRX (~$2.8M) as Chief R&D Officer. Net of sales, the recent Form 4 record there shows accumulation of 12,275 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2016 | CBIO Crescent Biopharma, Inc. | VP Clinical Development, CMO | Sell | 22,000 | $7.00 | $153,953.84 | -11.9% |